Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Topoisomerases: therapeutic value]

P Faure1, I Madelaine

  • 1Pharmacie, Hôpital Saint-Louis, Paris.

Annales Pharmaceutiques Francaises
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Anticancer drug development is advancing by targeting DNA topoisomerases, crucial nuclear enzymes involved in DNA replication and repair. New drugs targeting these enzymes show promise for improved cancer therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Virological diagnosis of anterior herpetic ocular disease on tear sample: A simple and non-invasive technique].

Journal francais d'ophtalmologie·2022
Same author

[A check-list in order to optimise the deployment of computerized medicine cabinets in a hospital: An essential support].

Annales pharmaceutiques francaises·2021
Same author

Multistep thermodesorption coupled with molecular analyses as a quick, easy and environmentally friendly way to measure PAH availability in contaminated soils.

Talanta·2021
Same author

Ambulatory high-dose methotrexate administration as central nervous system prophylaxis in patients with aggressive lymphoma.

Annals of hematology·2021
Same author

Management of cancer-related thrombosis in the era of direct oral anticoagulants: A comprehensive review of the 2019 ITAC-CME clinical practice guidelines. On behalf of the Groupe Francophone Thrombose et Cancer (GFTC).

Journal de medecine vasculaire·2020
Same author

Efficacy and tolerability on melasma of a topical cosmetic product acting on melanocytes, fibroblasts and endothelial cells: a randomized comparative trial against 4% hydroquinone.

Journal of the European Academy of Dermatology and Venereology : JEADV·2019
Same journal

[Artificial Intelligence in the Pharmaceutical Industry: Governance, Quality, and Regulatory Challenges].

Annales pharmaceutiques francaises·2026
Same journal

No evidence of significant natural environmental exposure to arsenic for Napoleon I on the island of Saint Helena (1815-1821).

Annales pharmaceutiques francaises·2026
Same journal

EFFECTS OF GLP-1 RECEPTOR AGONISTS ON PERIODONTAL TISSUE: AN INTERDISCIPLINARY EVIDENCE MAPPING - SCOPING REVIEW.

Annales pharmaceutiques francaises·2026
Same journal

Regulatory non-compliance of parallel imported medicines in Kenya and implications for public health: Evidence from Nairobi County.

Annales pharmaceutiques francaises·2026
Same journal

Prostaglandin analogues in cosmetic products formulated for eyelash lengthening.

Annales pharmaceutiques francaises·2026
Same journal

Mechanistic and thermodynamic evaluation of sodium citrate-mediated hydrotropism for the biopharmaceutical optimization of BCS Class II drug atorvastatin calcium.

Annales pharmaceutiques francaises·2026
See all related articles

Area of Science:

  • Pharmacology
  • Molecular Biology
  • Oncology

Context:

  • Anticancer drug discovery is rapidly evolving.
  • Understanding molecular cytotoxic mechanisms is key.
  • Novel compounds with distinct mechanisms of action are sought.

Purpose:

  • To explore the role of DNA topoisomerases as targets for anticancer agents.
  • To review current and emerging drugs targeting DNA topoisomerase I and II.
  • To assess the therapeutic potential of these agents in cancer treatment.

Summary:

  • DNA topoisomerases (I and II) are nuclear enzymes critical for DNA topology.
  • These enzymes are the targets of established cytotoxic agents (e.g., anthracyclines, etoposide) and novel compounds (e.g., irinotecan, topotecan).

Related Experiment Videos

  • Emerging drugs targeting both topoisomerase I and II are under investigation for enhanced efficacy.

    • Impact:

    • Advances in anticancer pharmacology offer new therapeutic design strategies.
    • Targeting DNA topoisomerases represents a significant area for developing novel cancer treatments.
    • Further research into dual topoisomerase inhibitors may yield synergistic effects and improved patient outcomes.